In this article the authors aimed to estimate the incidence of cerebral sinus and venous thrombosis (CVT) within one month from first-dose administration and the frequency of vaccine-induced immune thrombotic thrombocytopenia (VITT) as the underlying mechanism after vaccination.

This retrospective and multicenter registry included patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death).

In this retrospective, multicenter cohort study, the authors compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).

COVID-19 outcomes in patients with neurodegenerative disorders are not well understood, and the authors hypothesize there may be increased morbidity and mortality in this group. This retrospective cohort study was performed at three hospitals in the Chicagoland area.

In this article the authors compare SARS-CoV-2-specific CD4+ and CD8+ T cells against the B.1.1.7, B.1.351, P.1, and CAL.20C lineages in COVID-19 convalescents and in recipients of the Moderna (mRNA-1273) or Pfizer/BioNTech (BNT162b2) COVID-19 vaccines.

In this article the authors performed scRNA-seq on nasopharyngeal swabs from 58 healthy and COVID-19 participants.

On 15 May, 2021, the Virtual EAN-Day in Armenia took place, with more than 150 local medical professionals participating in the online event, including neurologists, residents, family doctors, rehabilitation specialists.

In this article the authors charted memory B cell receptor-encoded antibodies from 19 COVID-19 convalescent subjects against SARS-CoV-2 spike (S) and found 7 major antibody competition groups against epitopes recurrently targeted across individuals.

The objective of this study was to describe myocarditis presenting after COVID-19 vaccination within the Military Health System.

The objective of this study was to estimate the association between administration of IL-6 antagonists compared with usual care or placebo and 28-day all-cause mortality and other outcomes.

The objective of this randomized clinical trial was to determine whether oral azithromycin in outpatients with SARS-CoV-2 infection leads to absence of self-reported COVID-19 symptoms at day 14.

This randomized, double-blind, placebo-controlled phase 3 trial was conducted at 39 hospitals in Europe and the United States.

In this article the authors report cryo-EM structures of the full-length spike (S) trimers of the B.1.1.7 and B.1.351 variants, as well as their biochemical and antigenic properties.

In this article the authors combine cryo-EM, binding and computational analyses to study variant spikes, including one that was involved in transmission between minks and humans, and others that originated and spread in human populations.

A novel variant of concern (VOC) named CAL.20C (B.1.427/B.1.429), originally detected in California, carries spike glycoprotein mutations S13I in the signal peptide, W152C in the N-terminal domain (NTD), and L452R in the receptor-binding domain (RBD).